A compound targeting APOL2 and its uses

By regulating the expression and activity of APOL2 with small molecule compounds that target it, the problems of non-selective killing and drug resistance in existing tumor treatments have been solved, achieving highly efficient and low-toxicity treatment for a variety of malignant tumors.

CN123106466APending Publication Date: 2026-11-17INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610666612.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2025-05-16
Filing Date
2026-05-14
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing cancer treatment methods suffer from serious toxic side effects and drug resistance due to non-selective killing, while target mutations in targeted therapy limit long-term efficacy. There is an urgent need to discover novel tumor-specific targets such as APOL2.

Method used

Develop small molecule compounds that target APOL2, and regulate its expression and activity by binding to APOL2 with compounds of specific structures to achieve targeted therapy of tumor cells.

Benefits of technology

It improves the specificity and effectiveness of tumor treatment, reduces toxic side effects, prolongs the treatment effect, and is suitable for the treatment of various malignant tumors such as melanoma, breast cancer, and colorectal cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106466A_ABST
    Figure CN123106466A_ABST
Patent Text Reader

Abstract

The present application provides a kind of targeting APOL2 Small molecule compound and its use, targeting APOL2 Small molecule compound is as shown in formula I;Formula I compound targets activation APOL2 Expression and / or activity, regulates APOL2 Pathway, makes the tumor cell of expression APOL2 death, reaches anti-tumor effect.A‑(L1) n ‑B‑(L2) m ‑C(Formula I).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to an earlier application filed on May 16, 2025, with patent application number 2025106331561 and entitled "A Targeting APOL2 Compound and Its Use Therein". The entire contents of the earlier application are incorporated herein by reference. Technical Field

[0002] This invention belongs to the pharmaceutical field, specifically relating to a small molecule compound that targets APOL2 and its uses. Background Technology

[0003] Currently, cancer treatment mainly relies on chemotherapy, radiotherapy, and targeted therapy. However, traditional therapies cause serious toxic side effects (such as bone marrow suppression and organ damage) due to non-selective killing, and drug resistance is becoming increasingly prominent. Although targeted therapy significantly improves specificity (such as EGFR and HER2 inhibitors), drug resistance mechanisms caused by target mutations (such as the T790M mutation) limit long-term efficacy. Therefore, there is an urgent need to discover novel tumor-specific targets, especially key molecules that regulate tumor cell survival, metabolism, or immune escape.

[0004] Apolipoprotein L2 (APOL2) belongs to the apolipoprotein family, whose proteins are involved in lipid metabolism and cell membrane stability. Recent studies have revealed aberrant expression of APOL2 in tumors; elevated APOL2 expression in melanoma, breast cancer, colorectal cancer, bladder cancer, ovarian cancer, endometrial cancer, thyroid cancer, and malignant neurotumors is significantly positively correlated with patient prognosis and survival. Currently, no small-molecule antitumor drugs targeting APOL2 have been reported; therefore, developing such drugs has significant clinical therapeutic implications. Summary of the Invention

[0005] The first aspect of this invention provides a compound of Formula I, or a stereoisomer thereof, or a deuterated compound thereof, or a pharmaceutically acceptable salt thereof: A-(L1) n - B - (L2) m - C (Formula I); In formula I, n and m are each independent integers selected from 0, 1, 2, 3, 4, 5, 6, 7, and 8; A, B, and C are each independently selected from 5-10 membered aromatic rings, 5-10 membered aromatic heterocycles, 3-10 membered cycloalkyl groups, and 3-10 membered alkyl heterocycles; L1 and L2 are each independently selected from - R 3 -C(O)-R 4 -、- R 3 -C(O)N(R 5)R 4 -、- R 3 -C(O)OR 4 -、- R 3 -OR 4 -、- R 3 -N(R 4 )R 5 -、-(CH2) 0~4 -、-C 3~10 cycloalkyl, -C 3~10 Heterocyclic alkyl; the R 3 R 4 R 5 Selected independently from hydrogen and -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 The alkynyl group may not be present; In this invention, A, B, and C can be further optionally defined by one or more independent R. 1 replace; In this invention, L1 and L2 can be further optionally defined by one or more independent Rs. 2 replace; In the embodiments of the present invention, each L1 and L2 may be the same or different. When n and m are each independently selected from integers of 2, 3, 4, 5, 6, 7, and 8, -(L1) n - indicates that the same or different L1s are connected to each other in any combination and any order, - (L2) m - indicates that identical or different L2s can be connected to each other in any combination and any order.

[0006] In the embodiments of the present invention, both ends of L1 and L2 can be connected to adjacent structures. They can be connected to adjacent structures according to the writing format, that is, the left end of L1 is connected to A and the right end is connected to B, the left end of L2 is connected to B and the right end is connected to C. Alternatively, they can be connected to adjacent structures in the opposite direction of the writing format, that is, the right end of L1 is connected to A and the left end is connected to B, the right end of L2 is connected to B and the left end is connected to C.

[0007] In this invention, the R 1 R 2 Each group is independently selected from hydrogen, halogen, cyano, nitro, and -C. 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group, -C 0~4 Alkylene-OR 12 -C0~4 Alkylene-OC(O)R 12 -C 0~4 Alkylene-SR 12 -C 0~4 Alkylene-S(O)2R 12 -C 0~4 Alkylene-S(O)R 12 -C 0~4 Alkylene-S(O)2NR 12 R 13 -C 0~4 Alkylene-S(O)NR 12 R 13 -C 0~4 Alkylene-C(O)R 12 -C 0~4 Alkylene-C(O)OR 12 -C 0~4 Alkylene-C(O)NR 12 R 13 -C 0~4 Alkylene-NR 12 R 13 -C 0~4 Alkylene-NR 12 C(O)R 13 -C 0~4 Alkylene-NR 12 S(O)2R 13 -C 0~4 Alkylene-NR 12 S(O)R 13 -C 0~4 Alkylene (3- to 10-membered cycloalkyl), -C 0~4 Alkylene (3- to 10-membered heterocyclic alkyl), -C 0~4 alkylene-(6-10 membered aromatic ring), -C 0~4 Alkylene rings (5-10 membered heteroaryl rings); R 12 R 13 Selected independently from hydrogen and -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group, -C 0~4 Alkylene (3- to 10-membered cycloalkyl), -C 0~4 Alkylene (3- to 10-membered heterocyclic alkyl), -C 0~4 alkylene-(6-10 membered aromatic ring), -C 0~4Alkylene (5-10 membered heteroaryl ring); wherein the alkylene, cycloalkyl, heterocycloalkyl, aromatic ring, or heteroaryl ring may be optionally surrounded by one, two, three, or four independent R... 14 replace; The R 14 Each group is independently selected from hydrogen, halogen, cyano, nitro, and -C. 1~6 alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group, -C 0~4 Alkylene (3- to 10-membered cycloalkyl), -C 0~4 Alkylene (3- to 10-membered heterocyclic alkyl), -C 0~4 alkylene-(6-10 membered aromatic ring), -C 0~4 Alkylene rings (5-10 membered heteroaryl rings); In a specific embodiment of the present invention, A, B, and C are each independently selected from 6-membered aromatic rings, 6-membered aromatic heterocycles, 6-membered cycloalkyl groups, and 6-membered alkyl heterocycles; In a specific embodiment of the present invention, A, B, and C are each independently selected from benzene ring, naphthalene ring, pyridine ring, pyrimidine ring, cyclohexyl ring, and piperidine ring; In a specific embodiment of the present invention, L1 and L2 are each independently selected from: ; In a specific embodiment of the present invention, A is a benzene ring or a pyrimidine ring; In a specific embodiment of the present invention, B is a benzene ring or a piperidine ring; In a specific embodiment of the present invention, C is a benzene ring; In a specific embodiment of the present invention, n is 0 or 1; L1 is selected from: ; In a specific embodiment of the present invention, m is 1, 2, 3, or 4; L2 is selected from: ; In a specific embodiment of the present invention, the R 1 R 2 Each is independently selected from hydrogen, chlorine, fluorine, methyl, ethyl, isopropyl, methoxy, ethoxy, benzyloxy, m-isopropylaniline, methyl, and dimethylamino. In a specific embodiment of the present invention, A, B, and C are benzene rings; In a specific embodiment of the present invention, n is 1; L1 is selected from: ; In a specific embodiment of the present invention, m is 2; -(L2) m -Selected from: -R 3 -OR 4 -R 3 -C(O)N(R 5 )R 4 -; The R 3 R 4 R 5 Selected independently from hydrogen and -C 1~6 Alkyl groups or none, wherein the L2 may further optionally be composed of one or more independent R groups. 2 Replace, R 2 Each independently selected from -C 0~4 Alkylene-C(O)OR 12 -C 0~4 Alkylene-C(O)NR 12 R 13 -C 0~4 Alkylene-NR 12 R 13 ;R 12 R 13 Selected independently from hydrogen and -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group; In a specific embodiment of the present invention, m is 3 or 4; the -(L2) m -Selected from: - R 3 -C(O)N(R 5 )R 4 -C 3~10 cycloalkyl-R 3 -C(O)N(R 5 )R 4 -R 3 -OR 4 - or - R 3 -C(O)N(R 5 )R 4 -C 3~10 cycloalkyl-R 3 -C(O)N(R 5 )R 4 -; The R 3 R4 R 5 Selected independently from hydrogen and -C 1~6 Alkyl groups or none, wherein the L2 may further optionally be composed of one or more independent R groups. 2 Replace, R 2 Each group is independently selected from hydrogen, halogen, cyano, nitro, and -C. 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group; In a specific embodiment of the present invention, m is 3 or 4; L2 is selected from: ; In a specific embodiment of the present invention, the R 1 Selected from hydrogen, chlorine, methyl, and methoxy; In a specific embodiment of the present invention, the R 2 Selected from hydrogen, fluorine, and methyl; In a specific embodiment of the present invention, A, B, and C are benzene rings; In a specific embodiment of the present invention, n is 1; L1 is selected from: ; In a specific embodiment of the present invention, m is 4; L2 is selected from: ; In a specific embodiment of the present invention, the R 1 Selected from hydrogen and methyl; In a specific embodiment of the present invention, the R 2 Selected from hydrogen, fluorine, and methyl; In a specific embodiment of the present invention, the compound represented by Formula I has the structure of Formula (I-1): A -L1- B -L2 - C (Equation I-1) Wherein, A is cyclohexyl, and B is... C is a phenyl group; L1 is selected from -R 3 -N(R 4 )R 5 -, L2 is selected from - R 3 -C(O)N(R 5 )R 4 -; The R 3 R 4 R 5 Selected independently from hydrogen and -C1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 The alkynyl group may not be present; The C may be further optionally defined by one or more independent Rs. 1 Replace, R 1 Independently selected from hydrogen, halogen, cyano, nitro, -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group; The L1 can be further optionally defined by one or more independent Rs. 2 Replace; the R 2 Independent selection from -C 0~4 Alkylene-C(O)OR 12 -C 0~4 Alkylene-C(O)NR 12 R 13 -C 0~4 Alkylene-NR 12 R 13 The R 12 R 13 Selected independently from hydrogen and -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 Alkyne group.

[0008] In a specific embodiment of the present invention, L1 is selected from: , .

[0009] In a specific embodiment of the present invention, L2 is selected from -C(O)NH-.

[0010] This invention provides a method for preparing a compound of formula (I-1), or its stereoisomer, or its deuterated compound, or its pharmaceutically acceptable salt, wherein the preparation method comprises: Compound I-1-1 was deprotected to yield compound I-1-2. Compound I-1-2 and compound I-1-3 were coupled to yield compound I-1-4. Further hydrolysis yielded compound I-1-5. Compound I-1-5 and compound I-1-6 were acylated to prepare compound (I-1), where T is an amino protecting group, X is a halogen, and M is a carbon group.1~6 alkyl:

[0011] In a specific embodiment of the present invention, the compound represented by formula I has the structure of formula (I-2): A -L1- B-(L2)4- C (Formula I-2) Wherein, A, B, and C are all phenyl groups, and the phenyl groups may be optionally converted by one or more independent R groups. 1 Replace, R 1 Independently selected from hydrogen, halogen, cyano, nitro, -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group; L1 is -R 3 -OR 4 -,-(L2)4- is- R 3 -C(O)N(R 5 )R 4 -C 3~10 cycloalkyl-R 3 -C(O)N(R 5 )R 4 -R 3 -OR 4 -, where C 3~10 The cycloalkyl group may be further optionally replaced by one or more independent R 2 Instead, the R 2 Independently selected from hydrogen, halogen, cyano, nitro, -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group, -C 0~4 Alkylene-OR 12 , The R 3 R 4 R 5 Selected independently from hydrogen and -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 The alkynyl group may not exist.

[0012] In a specific embodiment of the present invention, -(L2)4- is... .

[0013] In a specific embodiment of the present invention, L1 is -O-.

[0014] This invention provides a method for preparing a compound of formula (I-2), or its stereoisomer, or its deuterated compound, or its pharmaceutically acceptable salt, wherein the preparation method comprises: Compound I-2-1 is protected by a protecting group to obtain compound I-2-2. Further alkylation yields compound I-2-3. Compound I-2-5 is hydrolyzed to give compound I-2-6. Compound I-2-6 is reacted with a reducing agent to generate compound I-2-7. Further addition of a carboxyl protecting group yields compound I-2-8. Removal of the amino protecting group yields compound I-2-9. Compound I-2-9 and compound I-2-10 are acylated to give compound I-2-11. Further nucleophilic substitution yields compound I-2-12. Removal of the carboxyl protecting group yields compound I-2-13. Compound I-2-13 and compound I-2-3 are acylated to give compound (I-2), where T is an amino protecting group, W is a hydroxyl protecting group, Z is a carboxyl protecting group, and M is a C6 protecting group. 1~6 Alkyl group, Q is C 3~10 Cycloalkyl groups, where R' is the group remaining after removing one carbon from R4:

[0015] In a specific embodiment of the present invention, the compound represented by formula I has the structure of formula (I-3): A -L1- B-(L2)2- C (Formula I-3) Wherein, A, B, and C are all phenyl groups, and the phenyl groups may be optionally converted by one or more independent R groups. 1 Replace, R 1 Independently selected from hydrogen, halogen, cyano, nitro, -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group, -C 0~4 Alkylene-OR 12 ; L1 is selected from -R 3 -N(R 4 )R 5 -,-(L2)2- is selected from -R 3 -OR 4 -R 3 -C(O)N(R 5 )R 4-; The R 3 R 4 R 5 Selected independently from hydrogen and -C 1~6 Alkyl groups may not be present; The L2 can be further optionally defined by one or more independent Rs. 2 Replace; the R 2 Independent selection from -C 0~4 Alkylene-C(O)OR 12 -C 0~4 Alkylene-C(O)NR 12 R 13 ; The R 12 R 13 Selected independently from hydrogen and -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 Alkyne group.

[0016] In a specific embodiment of the present invention, L1 is selected from -NH-CH2-.

[0017] In a specific embodiment of the present invention, -(L2)2- is selected from... , .

[0018] This invention provides a method for preparing a compound of formula (I-3), or its stereoisomer, or its deuterated compound, or its pharmaceutically acceptable salt, wherein the preparation method comprises: Compound I-3-3 is obtained by condensation and reduction of compound I-3-1 and compound I-3-2. Compound I-3-3 and compound I-3-4 are then acylated to obtain compound (I-3).

[0019] In a specific embodiment of the present invention, the compound represented by formula I has the structure of formula (I-4): A -L1- B - C (Equation I-4) Wherein, A and C are both phenyl, and B is... ; A, B, and C can be further arbitrarily selected by one or more independent R... 1 Replace, R 1 Independently selected from hydrogen, halogen, cyano, nitro, -C 1~6 Alkyl, -C 2~6 alkenyl, -C2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group, -C 0~4 Alkylene-OR 12 -C 0~4 Alkylene-C(O)OR 12 -C 0~4 Alkylene-C(O)NR 12 R 13 -C 0~4 Alkylene-NR 12 R 13 ; R 12 R 13 Selected independently from hydrogen and -C 1~6 Alkyl, -C 0~4 Alkylene (6-10 membered aromatic rings); L1 is selected from -R 4 -N(R 5 )C(O)R 3 -, the R 3 R 4 R 5 Selected independently from hydrogen and -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 The alkynyl group may not exist.

[0020] In a specific embodiment of the present invention, L1 is selected from -CH2CH2-NHC(O)-.

[0021] This invention provides a method for preparing a compound of formula (I-4), or its stereoisomer, or its deuterated compound, or its pharmaceutically acceptable salt, wherein the preparation method comprises: Compound I-4-3 is obtained by acylation of compound I-4-1 and compound I-4-2. Compound I-4-3 then reacts with a boric acid compound containing a cyclic C structure to obtain compound (I-4), where X is a halogen, such as fluorine, chlorine, or bromine.

[0022] In a specific embodiment of the present invention, the compound represented by formula I has the structure of formula (I-5): A - B - L2 - C (Equation I-5) The A is B is C is a phenyl group; A, B, and C can be further arbitrarily selected by one or more independent R...1 Replace, R 1 Independently selected from hydrogen, halogen, cyano, nitro, -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group, -C 0~4 Alkylene-OR 12 -C 0~4 Alkylene-C(O)OR 12 -C 0~4 Alkylene-C(O)NR 12 R 13 -C 0~4 Alkylene-NR 12 R 13 ; L2 is -R 3 -C(O)N(R 5 )R 4 -, the R 3 R 4 R 5 Selected independently from hydrogen and -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 The acetylin group may not be present. The L2 can be further optionally defined by one or more independent Rs. 2 Replace; the R 2 Independent selection from -C 0~4 Alkylene-C(O)OR 12 -C 0~4 Alkylene-C(O)NR 12 R 13 -C 0~4 Alkylene-NR 12 R 13 ; The R 12 R 13 Selected independently from hydrogen and -C 1~6 Alkyl, -C 0~4 Alkylene (6-10 membered aromatic ring); wherein the aromatic ring may be optionally surrounded by one, two, three or four independent R... 14 replace; The R 14 Each group is independently selected from hydrogen, halogen, cyano, nitro, and -C. 1~6 Alkyl groups.

[0023] In a specific embodiment of the present invention, L2 is selected from... , .

[0024] This invention provides a method for preparing a compound of formula (I-5), or its stereoisomer, or its deuterated compound, or its pharmaceutically acceptable salt, wherein the preparation method comprises: Compound I-5-3 is obtained by acylation of compound I-5-1 and compound I-5-2. Compound I-4-3 reacts with a boric acid compound containing a ring A structure to obtain compound (I-5), where X is a halogen, such as fluorine, chlorine, or bromine.

[0025] In a specific embodiment of the present invention, the compound of formula I is specifically:

[0026] TM-2,

[0027] TM3

[0028] TM-1,

[0029] TM-4

[0030] TM-5.

[0031] In a second aspect, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of at least one of the compounds represented by Formula I, or a stereoisomer thereof, or a deuterated compound thereof, or a pharmaceutically acceptable salt thereof.

[0032] According to embodiments of the present invention, the pharmaceutical composition further includes one, two, or more pharmaceutically acceptable excipients.

[0033] According to an embodiment of the invention, the pharmaceutical composition further comprises one or more additional therapeutic agents.

[0034] According to embodiments of the present invention, the pharmaceutical composition further comprises one or more additional drugs for treating or preventing cancer.

[0035] According to the present invention, the pharmaceutical compositions of the present invention can be formulated into dosage forms suitable for administration by methods known in the art.

[0036] The third aspect of the present invention provides the use of the compound described in the first aspect above, or its stereoisomer, or its deuterated compound, or its pharmaceutically acceptable salt, or the pharmaceutical composition described in the second aspect above, in the preparation of a medicament for treating diseases related to abnormal cell proliferation.

[0037] In this invention, the disease is a tumor-related disease; The present invention also provides the use of any of the compounds described above, or stereoisomers thereof, or deuterated compounds thereof, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the preparation of medicaments for treating tumors.

[0038] The present invention also provides the use of any of the compounds described above, or stereoisomers thereof, or deuterated compounds thereof, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the preparation of a medicament targeting APOL2.

[0039] In another aspect of the invention, the invention provides the use of the compound of Formula I described above, or a stereoisomer thereof, or a deuterated compound thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the preparation of a medicament for treating cancer in an individual or delaying the progression of cancer in an individual; Furthermore, the drug is a drug that targets APOL2; In a specific embodiment of the present invention, the tumor is selected from liver cancer, breast cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, medulloblastoma, melanoma, non-small cell lung cancer, small cell lung cancer, cervical cancer, ovarian cancer, bladder cancer, thyroid cancer, head and neck cancer, prostate cancer, fibroblastoma, leukemia, myeloma, and lymphoma.

[0040] A fourth aspect of the present invention provides a method for promoting tumor cell death, comprising using drug molecules to target and activate APOL2 expression and / or activity, regulating the APOL2 pathway, and causing tumor cells expressing APOL2 to die; In this invention, the drug molecule is a chemical drug or a biological drug; Further, the chemical drug is the pharmaceutical composition defined in Formula I above or the pharmaceutical composition described in the second aspect above; Furthermore, the chemical drug is defined as described in the definition of the compound in the first aspect above; In one aspect of the invention, the invention provides a method for reducing tumor size or inhibiting tumor growth in a tumor subject in need, comprising administering an effective amount of the compound of formula I described above to the subject; wherein the compound of formula I targets and binds to APOL2; Furthermore, the terms in the compound of formula I are defined as described in the first aspect above; Furthermore, in this invention, the above-described method may further include administering immune checkpoint blockade therapy and / or oncolytic virus therapy to the subject in combination; Furthermore, the immune checkpoint blockade therapy is the administration of an immune checkpoint inhibitor; In a specific embodiment of the present invention, the immune checkpoints may include, but are not limited to, PD-1 and / or CTLA4; In a fifth aspect, the present invention provides a combined antitumor treatment method, wherein the combined antitumor treatment method is a combination of targeted binding to APOL2 with immune checkpoint blockade therapy, adoptive immune cell therapy, and / or oncolytic virus therapy, and is administered to tumor subjects in need. In a specific embodiment of the present invention, the tumor is a solid tumor or a non-solid tumor; In this invention, the above-described method administers the compound of Formula I by oral administration or by intradermal, subcutaneous, intraperitoneal, intratumoral, intramuscular, intravenous, arterial, intrathecal injection or intracavitary administration or a combination thereof. In this invention, the application of the compound of formula I includes direct application or application of a composition containing the compound of formula I; wherein the composition further comprises pharmaceutically acceptable excipients; In this invention, "pharmaceuticalally acceptable excipients" include any solvent, dispersion medium, coating material, surfactant, antioxidant, preservative (e.g., antibacterial, antifungal), isotonic agent, salt, pharmaceutical stabilizer, binder, excipient, dispersant, lubricant, sweetener, flavoring agent, colorant, or combinations thereof, all of which are known to those skilled in the art (as described in Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329). The use of these carriers in therapeutic or pharmaceutical compositions is covered, except in cases where any conventional carrier is incompatible with the active ingredient.

[0041] The effective dosage described in this invention can vary depending on the administration method and the severity of the disease to be treated. A preferred effective dosage can be determined by those skilled in the art based on various factors (e.g., through clinical trials). These factors include, but are not limited to: pharmacokinetic parameters of the bioactive ingredient, such as bioavailability, metabolism, and half-life; the severity of the disease to be treated, the patient's weight, the patient's immune status, and the route of administration. For example, due to the urgency of the treatment, several separate doses may be administered daily, or the dose may be reduced proportionally.

[0042] The compositions of the present invention can be incorporated into medicaments suitable for parenteral administration (e.g., intradermal, subcutaneous, intraperitoneal, intratumoral, intramuscular, intravenous, arterial, intrathecal, intracavitary). These medicaments can be prepared in various forms, such as liquids, semi-solids, and solid dosage forms, including but not limited to liquid solutions (e.g., injectable solutions and infusion solutions) or lyophilized powders.

[0043] The compounds or compositions of the present invention are administered using typical pharmaceutical routes, such as oral solid dosage forms and injectable liquid dosage forms. The compounds or compositions of the present invention can be administered orally, intravenously, by injection, intramuscularly, or subcutaneously, specifically by oral administration or intradermal, subcutaneous, intraperitoneal, intratumoral, intramuscular, intravenous, arterial, intrathecal, or intracavitary administration, or a combination thereof.

[0044] The compounds and derivatives provided in this invention can be named according to the IUPAC (International Union of Pure and Applied Chemistry) or CAS (Chemical Abstracts Service, Columbus, OH) nomenclature systems.

[0045] Regarding the definition of terms used in this invention: Unless otherwise stated, the initial definitions provided for groups or terms herein apply to the groups or terms used throughout this specification; for terms not specifically defined herein, the meanings that a person skilled in the art would give them should be given based on the disclosure and context.

[0046] "Substitution" refers to the replacement of hydrogen atoms in a molecule by other different atoms or molecules. "Substitution" can also refer to the replacement of lone pairs of electrons in atoms in a molecule by "=O", "=S", etc.

[0047] "Can be further replaced" means that "replacement" can but does not have to happen, and this statement includes situations where it may or may not happen.

[0048] The minimum and maximum carbon atom content in hydrocarbon groups are indicated by a prefix, for example, the prefix C. a~b Alkyl indicates any alkyl group containing one to two carbon atoms ("a" to "b"). Therefore, for example, "C..." 1~4 "Alkyl" refers to an alkyl group containing 1 to 4 carbon atoms.

[0049] "Alkyl" refers to a saturated hydrocarbon chain having a specified number of member atoms. For example, C1-6 alkyl refers to an alkyl group having 1 to 6 member atoms, such as 1 to 4 member atoms. Alkyl groups can be straight-chain or branched. Representative branched alkyl groups have one, two, or three branches. Alkyl groups may optionally be substituted by one or more substituents as defined herein. Alkyl groups include methyl, ethyl, propyl (n-propyl and isopropyl), butyl (n-butyl, isobutyl, and tert-butyl), pentyl (n-pentyl, isopentyl, and neopentyl), and hexyl. Alkyl groups may also be part of other groups, such as C1-6 alkoxy groups.

[0050] In this invention, "alkylene" refers to a divalent saturated aliphatic hydrocarbon group having a specified number of carbon atoms. "C" a ~ b "Alkylene" refers to an alkylene group having a to b carbon atoms. Alkylene groups include branched and straight-chain hydrocarbon groups. For example, "C 1~6 "alkylene" is intended to include methylene, ethylene, propylene, 2-methylpropylene, dimethylethylene, pentylene, etc. Furthermore, the term "(C1-6)alkylene" is intended to include such branched hydrocarbon groups, such as cyclopropylmethylene, which can be exemplified by the following structures: For example, -C0~4 alkylene groups can be C0 alkylene, C1 alkylene (e.g., -CH2-), C2 alkylene (e.g., -CH2CH2-), C3 alkylene, or C4 alkylene; C0 alkylene refers to the absence of a group here, which is connected by a chemical bond. For example, A-C0 alkylene-B refers to AB, that is, the A group and the B group are directly connected by a chemical bond.

[0051] "Alkenyl" refers to a straight-chain or branched hydrocarbon group having a specified number of carbon atoms and, in some embodiments, 2 to 6 carbon atoms or 2 to 4 carbon atoms and having at least one vinyl unsaturated site (>C=C<). For example, C a-b Alkenyl refers to an alkenyl group having a to b carbon atoms and is intended to include, for example, vinyl, propenyl, isopropenyl, 1,3-butadienyl, etc.

[0052] In this invention, "alkenyl" refers to a hydrocarbon chain having 2 to 10 carbon atoms, at least one double bond, and two unsaturated valences. For example, (C3-C6) alkenyl groups include >C=CH-CH2-, -CH-CH=CH-CH2-, etc.

[0053] "Alynyl" refers to a straight-chain monovalent hydrocarbon group or a branched monovalent hydrocarbon group containing at least one triple bond. The term "alkynyl" is also intended to include hydrocarbon groups having one triple bond and one double bond. For example, (C2-C6) alkynyl is intended to include ethynyl, propynyl, etc.

[0054] "Halogen" refers to fluorine, chlorine, bromine, or iodine.

[0055] "Halogenated alkyl" or "halogen-substituted alkyl" refers to an alkyl group in which one or more hydrogen atoms can be replaced by one or more halogen atoms. For example, C 1~4 Halogenated alkyl refers to an alkyl group containing 1 to 4 carbon atoms in which one or more hydrogen atoms are replaced by one or more halogen atoms.

[0056] In this invention, “-OR*”, “-NR*R**”, etc., refer to R* or R** groups that are connected to oxygen or nitrogen atoms by a single bond.

[0057] In this invention, the oxygen atom in “-C(O)R*”, “-S(O)2R*”, etc., is connected to the carbon atom or sulfur atom by a double bond, and the R group is connected to the oxygen atom or sulfur atom by a single bond.

[0058] In this invention, "cycloalkyl" refers to a saturated or partially saturated cyclic group having multiple carbon atoms and no heterocyclic atoms, and having a single ring or multiple rings (including fused, bridged, spirocyclic, and adamantane systems). For polycyclic systems having aromatic and non-aromatic rings without heteroatoms, the term "cycloalkyl" (e.g., 5, 6, 7, 8,-tetrahydronaphthalene-5-yl) applies when the connecting point is located on a non-aromatic carbon atom. The term "cycloalkyl" includes cycloalkenyl groups, such as cyclohexenyl. Examples of cycloalkyl groups include, for example, adamantyl, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclooctyl, cyclopentenyl, and cyclohexenyl. Examples of cycloalkyl groups including polycyclic dicycloalkyl ring systems are dicyclohexyl, dicyclopentyl, dicyclooctyl, etc. , , Adamantyl groups include, but are not limited to, the following structures: .

[0059] In this invention, "heterocyclic" and "heterocyclic alkyl" refer to a saturated ring or a non-aromatic unsaturated ring containing at least one heteroatom; where the heteroatom refers to nitrogen, oxygen, sulfur, etc. Generally, it represents a monovalent saturated or partially unsaturated monocyclic or bicyclic ring system with multiple ring atoms, preferably a monovalent saturated or partially unsaturated monocyclic or bicyclic ring system with 3 to 9 ring atoms, containing 1, 2, or 3 cyclic heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon. A bicyclic ring refers to a ring consisting of two rings sharing two ring atoms, i.e., the bridge separating the two rings is a single bond or a chain of one or two ring atoms. Examples of monocyclic saturated heterocyclic alkyl groups are oxobutyl, aziridine, pyrrolidinyl, 2-oxo-pyrrolidin-3-yl, tetrahydrofuranyl, tetrahydro-thiophenyl, pyrazolyl, imidazoalkyl, thiazoalkyl, piperidinyl, tetrahydropyranyl, tetrahydrothiaranyl, piperazine, morpholinyl, etc. Thiomorpholinyl, 1,1-dioxo-thiomorpholin-4-yl, azirmonyl, diazarmonyl, periperazinyl, or oxazarmonyl. Examples of bicyclic saturated heterocyclic alkyl groups are 8-aza-bicyclo[3.2.1]octyl, quininecycloyl, 8-oxa-3-aza-bicyclo[3.2.1]octyl, 9-aza-bicyclo[3.3.1]nonyl, Examples of partially unsaturated heterocyclic alkyl groups are dihydrofuranyl, imidazolinyl, tetrahydropyridyl, or dihydropyranyl.

[0060] In this invention, "aromatic ring" and "aryl" refer to aromatic hydrocarbon groups having multiple carbon atoms. Aryl groups are typically monocyclic, bicyclic, or tricyclic aryl groups having 5-20 carbon atoms. Furthermore, the term "aryl" as used herein refers to an aromatic substituent that can be a single aromatic ring or multiple aromatic rings fused together. Non-limiting examples include phenyl, naphthyl, or tetrahydronaphthyl.

[0061] In this invention, "aromatic heterocycle" refers to an aromatic unsaturated ring containing at least one heteroatom; wherein the heteroatom refers to a nitrogen atom, an oxygen atom, or a sulfur atom. Typically, it refers to an aromatic monocyclic or bicyclic hydrocarbon containing multiple ring atoms, one or more of which are selected from O, N, and S heteroatoms. Preferably, it has one to three heteroatoms. Examples of heterocyclic aryl groups include: pyridyl, indolyl, quinoxalinyl, quinolinyl, isoquinolinyl, benzothiopheneyl, benzofuranyl, benzothiopheneyl, benzopyranyl, benzothiapyranyl, furanyl, pyrroleyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazoleyl, thiopheneyl, oxadiazolyl, benzimidazoleyl, benzothiazolyl, and benzoxazolyl.

[0062] "Stereoisomers" include enantiomers and diastereomers; The "deuterated compound" of this invention refers to a molecule or group in which one or more hydrogen atoms are replaced by deuterium atoms, wherein the proportion of deuterium atoms is greater than the abundance of deuterium in nature.

[0063] The term "pharmaceutically acceptable" means that a carrier, delivery substance, diluent, excipient, and / or the salt formed therefrom is generally chemically or physically compatible with other components constituting a drug dosage form and physiologically compatible with receptors.

[0064] The terms "salt" and "pharmaceutically acceptable salt" refer to acidic and / or basic salts formed by the above-described compounds or their stereoisomers with inorganic and / or organic acids and bases, including zwitterionic salts (internal salts) and quaternary ammonium salts, such as alkylammonium salts. These salts can be obtained directly during the final separation and purification of the compounds. Alternatively, they can be obtained by mixing the above-described compounds, or their stereoisomers, with an appropriate amount (e.g., equimolar amounts) of an acid or base. These salts may be obtained by precipitating in solution and collecting by filtration, or by recovery after solvent evaporation, or by freeze-drying after reaction in an aqueous medium. The salts described in this invention can be hydrochlorides, sulfates, citrates, benzenesulfonates, hydrobromides, hydrofluoric acids, phosphates, acetates, propionates, succinates, oxalates, malates, succinates, fumarates, maleates, tartrates, or trifluoroacetates of the compounds.

[0065] Obviously, based on the above description of the present invention, and according to common technical knowledge and conventional methods in the field, various other modifications, substitutions or alterations can be made without departing from the basic technical concept of the present invention. Attached Figure Description

[0066] Figure 1 The bar chart shows the cytotoxicity assay of the TM-1 compound in Experimental Example 9. Figure 2 The bar chart shows the cytotoxicity assay of the TM-2 compound in Experimental Example 9; Figure 3 The bar chart shows the cytotoxicity assay of the TM-3 compound in Experimental Example 9; Figure 4 The bar chart shows the cytotoxicity assay of the TM-4 compound in Experimental Example 9. Figure 5 The bar chart shows the cytotoxicity assay of the TM-5 compound in Experimental Example 9. Detailed Implementation

[0067] The following detailed embodiments further illustrate the above-described content of the present invention. However, this should not be construed as limiting the scope of the present invention to the following examples. All technologies implemented based on the above-described content of the present invention fall within the scope of the present invention.

[0068] It should be noted that, regarding the technical solutions disclosed in the embodiments or implementation schemes of this invention, this invention intends to cover all alternative, modified, and equivalent technical solutions, all of which are included within the scope of this invention. Those skilled in the art should recognize that many similar or equivalent methods and materials can be used to practice this invention. This invention is by no means limited to the methods and materials described herein. In the event that one or more of the cited documents, patents, and similar materials differ from or contradict this application (including but not limited to defined terminology, terminology application, described techniques, etc.), this invention shall prevail.

[0069] It should be further appreciated that certain features of the invention, for clarity, have been described in multiple independent embodiments or implementations, but may also be provided in combination in a single embodiment or implementation. Conversely, various features of the invention, for brevity, have been described in a single embodiment or implementation, but may also be provided individually or in any suitable sub-combination.

[0070] Definitions and explanations: Unless otherwise indicated, the technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains, and unless otherwise indicated, all patent publications cited in the entirety of this disclosure are incorporated herein by reference.

[0071] In this document, the terms “comprising” or “including” are open-ended expressions, meaning that they include the contents specified in this invention, but do not exclude other aspects.

[0072] In this document, the terms “optionally,” “optionally,” or “optionally” generally refer to an event or condition that may, but may not, occur, and the description includes both cases in which the event or condition occurs and cases in which the event or condition does not occur.

[0073] In this document, the term "pharmaceutically acceptable" means that a substance or composition must be chemically and / or toxicologically compatible with other components of the formulation and / or the mammals to which it is treated.

[0074] In this document, the term "one or more" (e.g., in the definition of substituents in compounds of the general formula of the present invention) means "one, two, three, four or five, especially one, two, three or four, more especially one, two or three, and even more especially one or two".

[0075] In this document, the term "treatment" refers to the use of drugs to achieve desired pharmacological and / or physiological effects. These effects may be preventative in terms of complete or partial prevention of disease or its symptoms, and / or therapeutic in terms of partial or complete cure of disease and / or adverse effects caused by disease. As used herein, "treatment" encompasses diseases in mammals, particularly humans, including: (a) prevention of disease or the onset of disease in susceptible individuals who have not yet been diagnosed with the disease; (b) inhibition of disease, such as blocking disease progression; or (c) relief of disease, such as reducing disease-related symptoms. As used herein, "treatment" encompasses any administration of a drug or compound to an individual to treat, cure, relieve, improve, reduce, or inhibit the individual's disease, including but not limited to administration of a drug containing a compound described herein to an individual in need.

[0076] The effective dosage described in this invention can vary depending on the administration method and the severity of the disease to be treated. A preferred effective dosage can be determined by those skilled in the art based on various factors (e.g., through clinical trials). These factors include, but are not limited to: pharmacokinetic parameters of the bioactive ingredient, such as bioavailability, metabolism, and half-life; the severity of the disease to be treated, the patient's weight, the patient's immune status, and the route of administration. For example, due to the urgency of the treatment, several separate doses may be administered daily, or the dose may be reduced proportionally.

[0077] The known starting materials of this invention can be synthesized using or according to methods known in the art, or can be purchased from companies such as Anaiji Chemical, Chengdu Kelong Chemical, Shaoyuan Chemical Technology, and Bailingwei Technology.

[0078] Unless otherwise specified in the examples, the reaction temperature is room temperature. Room temperature is the optimal reaction temperature, which is 20°C to 30°C. Unless otherwise specified in the examples, M represents moles per liter.

[0079] The structure of the compound was determined by nuclear magnetic resonance (NMR) and mass spectrometry (MS). NMR shifts (δ) are given in units of 10⁻⁶ (ppm). NMR measurements were performed using a Bruker Avance III 400 and a Bruker Avance 600 NMR spectrometer, with deuterated dimethyl sulfoxide (DMSO) as the solvent. d 6 ), deuterated chloroform (CDCl3), deuterated methanol (Methol- d 4The internal standard was tetramethylsilane (TMS). LC-MS was performed using a Shimadzu LC-MS 2020 (ESI) system. HPLC was performed using a Shimadzu LC-20A high-performance liquid chromatograph. MPLC (medium-pressure preparative chromatography) was performed using a Gilson GX-281 reversed-phase preparative chromatograph. Thin-layer chromatography used Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates, with a thickness of 0.4 mm to 0.5 mm for product separation and purification. Column chromatography generally used Yantai Huanghai 200-300 mesh silica gel as the carrier.

[0080] In this specific embodiment, the general synthetic method for compound I is as follows: Method 1: Sequential synthesis starting from one end of the compound of formula I: A was synthesized and connected to one end of L1, and then the other end of L1 was synthesized and connected to B. L2 and C were connected in sequence to prepare compound I. Alternatively, C can be synthesized and connected to one end of L2, and then B, L1, and A can be connected sequentially to prepare compound I. Method 2: Combine segments, then connect and combine as needed: L1 and L2 were synthesized separately, and then connected with A, B, and C to prepare compound I. Alternatively, L1 can be synthesized and then connected to A and B, or L2 can be synthesized and then connected to B and C, and then compound I can be prepared. Method 3: Flexible on-demand connection and synthesis: According to the specific structure of the target formula I, the target compound is synthesized in a manner other than Method 1 and Method 2, for example, by using functional groups as reaction linkage sites: A and part of the structure of L1 are used as starting materials, and B and another part of the structure of L1 are used as reaction participants to synthesize A-L1-B, and then the next step of synthesis linkage is carried out; finally, the compound of formula I is prepared.

[0081] The following are examples of specific compounds, used to representatively illustrate the preparation of compounds of Formula I of the present invention, and are not intended to limit the synthesis of compounds of Formula I: Example 1: Synthesis of TM-2 Synthesis route: (1) (2) (3)

[0084] Synthesis operation: Step 1: Synthesis of Intermediate 2 A clean, 25 mL oval-shaped flask was used as the reaction vessel. Commercial raw material 1, 2-(2,4-dimethylphenoxy)ethanamine hydrochloride (330.0 mg, 2 mmol), was dissolved in a mixture of tetrahydrofuran (3 mL) and water (1 mL). Anhydrous sodium carbonate (423.4 mg, 3.99 mmol) and di-tert-butyl dicarbonate (435.39 mg, 2.00 mmol) were added with stirring at room temperature. The mixture was stirred overnight at 20 °C. The reaction was quenched with 1 M dilute hydrochloric acid, and the pH was adjusted to 6-7. The mixture was extracted three times with ethyl acetate. The combined phases were dried over anhydrous sodium sulfate, and the solvent was removed to obtain crude intermediate 2 (0.49 g, crude product). LCMS [M+H]+ m / z: 266.0.

[0085] Step 2: Synthesis of the middle 3 A clean, 50 mL oval-shaped flask was used as the reaction vessel. Intermediate 2 (0.49 g, crude product) was dissolved in 10 mL of anhydrous tetrahydrofuran, and then lithium aluminum hydride (313.2 mg, 9.23 mmol) was slowly added at 0 °C. The mixture was then heated to 80 °C and reacted for 6 hours. The reaction was quenched by adding water and then NaOH solution sequentially. After removing the solvent, crude intermediate 3 (0.3 g, crude product) was obtained. LCMS [M+H]+ m / z: 180.1.

[0086] Step 3: Synthesis of Intermediate 5 A clean, 25 mL pear-shaped flask was used as the reaction vessel. Commercial raw material 4 (6.4 g, 49.95 mmol) and zinc diiodide (160 mg, 0.5 mmol) were added to the vessel in sequence. After stirring for 10 minutes, trimethylcyanosilane (5 mL) was added under ice bath conditions. After incubation at room temperature overnight, the solvent was directly evaporated to obtain intermediate 5 (11 g, crude product).

[0087] Step 4: Synthesis of Intermediate 6 A clean, 50 mL orb-shaped flask was used as the reaction vessel. Intermediate 5 (11.0 g, crude) was dissolved in 10 mL of acetonitrile and 4 mL of water. Lithium hydroxide hydrate (2.0 g, 48.39 mmol) was added with stirring at room temperature. After stirring overnight at room temperature, intermediate 6 was purified to obtain intermediate 6 (1.0 g, 7.09 mmol, 14.64% yield). LCMS [MH]+ m / z: 140.0.

[0088] Step 5: Synthesis of Intermediate 7 A clean, 50 mL or g-shaped flask was used as the reaction vessel. Intermediate 6 (1.0 g, 7.09 mmol) was dissolved in 10 mL of methanol. Anhydrous nickel chloride (800.5 mg, 8.50 mmol), di-tert-butyl dicarbonate (1.85 g, 8.50 mmol), and then sodium borohydride (1.85 g, 8.50 mmol) were added sequentially in portions under stirring in an ice bath. The reaction was carried out at 0 °C for 2 hours, then quenched with water under ice bath conditions. After filtration, the solvent was removed from the filtrate to obtain intermediate 7 (0.6 g, crude product). LCMS [M+H]+ m / z: 246.1. Step 6: Synthesis of Intermediate 8 A clean, 50 mL orb-shaped flask was used as the reaction vessel. Intermediate 7 (0.6 g, crude) was dissolved in 5 mL of N,N-dimethylformamide. Anhydrous potassium carbonate (1.01 g, 7.34 mmol) and benzyl bromide (527.2 mg, 4.89 mmol) were added sequentially with stirring, and the mixture was stirred overnight at room temperature. The purified solution was then added to intermediate 8 (0.28 g, 834.84 μmol, 34.13% yield). LCMS [M+H]+ m / z: 336.3. Step 7: Synthesis of Intermediate 9 A clean, 25 mL orb-shaped flask was used as the reaction vessel. Intermediate 8 (0.28 g, 834.84 μmol) was dissolved in 1 mL of dichloromethane, and TFA (95.2 mg, 1 mL) was added with stirring. The mixture was stirred at room temperature for 1 hour. The solvent was removed from the reaction solution to obtain intermediate 9 (0.12 g, crude product). LCMS [M+H]+ m / z: 236.3. Step 8: Synthesis of Intermediate 11 A clean, 25 mL pear-shaped flask was used as the reaction vessel. Intermediate 9 (0.12 g, crude) and commercial starting material 10 (125.0 mg, 515.95 μmol) were dissolved in 2 mL of N,N-dimethylformamide. N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (171.4 mg, 612.04 μmol) was dissolved in 0.5 mL of N,N-dimethylformamide, followed by the addition of N-methylimidazole (0.1 mL). The mixture was shaken well in a centrifuge tube and added to the 25 mL reaction flask. The reaction was carried out at room temperature for 1 hour. The mixture was purified by HPLC and concentrated to obtain intermediate 11 (100.0 mg, 217.61 μmol, 42.67% yield). LCMS [M+H]+ m / z: 460.5. Step 9: Synthesis of Intermediate 12

[0089] A clean, 25 mL orb-shaped flask was used as the reaction vessel. Intermediate 11 (100.0 mg, 217.61 μmol) was dissolved in 2 mL of dichloromethane and placed in an ice-water bath. Then, under nitrogen protection, a dichloromethane mixture of thiomorpholine trifluoride (76.2 mg, 435.23 μmol) was added dropwise. The reaction was carried out at room temperature for 2 hours. The reaction was quenched with water, and the solvent was removed. The mixture was then purified to obtain intermediate 12 (52.0 mg, 112.67 μmol, 51.78% yield).

[0090] LCMS [M+H]+ m / z:462.2. Step 10: Synthesis of Intermediate 13 A clean, 25 mL orb-shaped flask was used as the reaction vessel. Intermediate 12 (52.0 mg, 112.67 μmol) was dissolved in a mixture of acetonitrile (1 mL) and water (0.5 mL), and sodium hydroxide (18.0 mg, 450.68 μmol) was added. The reaction was carried out at room temperature for 4 h. The pH was adjusted to 5-6 with 1 M dilute hydrochloric acid to quench the reaction. The mixture was extracted three times with ethyl acetate, and the organic phase was dried over anhydrous sodium sulfate and concentrated to obtain crude intermediate 13 (40 mg, crude product). LCMS [M+H]+ m / z: 372.0. Step 11: Synthesis of the final product TM-2 A clean, 25 mL orb-shaped flask was used as the reaction vessel. Intermediate 13 (40.0 mg, crude) and Intermediate 3 (45.0 mg, 251.03 μmol) were dissolved in 2 mL of N,N-dimethylformamide. N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (36.19 mg, 129.24 μmol) was dissolved in 0.5 mL of N,N-dimethylformamide, followed by the addition of N-methylimidazole (0.1 mL). The mixture was then shaken well and added to the 25 mL reaction flask. The reaction was carried out at room temperature for 1 hour. The colorless oily compound TM-2 (24.1 mg, 45.25 μmol, 42.0% yield, 96.3% purity HPLC) was purified by HPLC.

[0091] LCMS [M+H]+ m / z: 533.6 1 H NMR (600 MHz, Methanol- d 4) δ 7.32 (ddd, J = 8.7, 7.4, 1.6 Hz, 2H),7.25 (q,J = 7.9 Hz, 1H), 7.12 – 7.03 (m, 2H), 7.00 (dt, J = 8.4, 2.1 Hz, 1H), 6.98 – 6.85 (m, 4H), 6.85 – 6.79 (m, 1H), 6.75 (dd, J = 8.4, 2.9 Hz, 1H), 4.06(dt, J = 12.0, 5.2 Hz, 2H), 3.80 – 3.38 (m, 6H), 3.01 (d, J = 41.0 Hz, 3H), 2.54– 2.27 (m, 4H), 2.21 (d, J = 6.2 Hz, 3H), 2.10 (d, J = 33.8 Hz, 3H), 1.39 (dd, J =17.4, 7.0 Hz, 3H). Example 2: Synthesis of TM-3 Synthesis route: (1) (2) (3)

[0094] Synthesis operation: Step 1: Synthesis of Intermediate 3 A clean, 50 mL oval-shaped flask was used as the reaction vessel. Commercial raw material 1 (155.0 mg, 599.25 μmol) and commercial raw material 2 (82.2 mg, 599.25 μmol) were dissolved in anhydrous methanol (4 mL). Glacial acetic acid (1 mL) was added at room temperature. The mixture was stirred at 20 °C for approximately 1 hour. Then, the reaction reagent Borane-2-picoline complex (146.8 mg, 1498.13 μmol, CAS: 110-51-0) was added at room temperature. The reaction mixture was stirred at 20 °C for approximately 2 hours. Post-reaction treatment: The reaction was quenched directly with water, purified, and lyophilized to obtain white intermediate 3. (200.0 mg, 526.6 μmol, 87.8% yield) LCMS [M+H]+ m / z: 380.1.

[0095] Step 2: Synthesis of Intermediate 5 A clean, 25 mL oval-shaped flask was used as the reaction vessel. Commercial reagent intermediate 4 (3S)-3-(tert-butoxycarbonylamino)-4-(3-chlorophenyl)butanoic acid (60.0 mg, 191.22 μmol) and methylamine hydrochloride (38.7 mg, 573.66 μmol) were weighed into the flask. Nitrile dimethylformamide (3 mL) was added at room temperature to dissolve the two reactants. Then, nitrile methylimidazolium (95.4 mg, 1.15 mmol) was added. Next, N,N,N',N'-tetramethylchloromethylammonium hexafluorophosphate (64.4 mg, 229.46 μmol) was added to the system at 0 °C. The reaction mixture was stirred at 0 °C for approximately 0.5 hours. The system was analyzed and detected using LCMS. After successful reaction, no further processing was required; the reaction solution was directly sent to a Prep-HPLC platform for further processing. The purified fraction was freeze-dried to give a white intermediate 5 (51.0 mg, 156.05 μmol, 81.61% yield) LCMS [M+H]+ m / z: 327.1.

[0096] Step 3: Synthesis of Intermediate 6 Intermediate 5 (51.0 mg, 156.05 μmol, 1 equivalent) was dissolved in dichloromethane, and trifluoroacetic acid (2 mL) was added with stirring. The mixture was stirred at room temperature for 30 min, and the reaction was monitored by LC-MS. After the reaction was completed, the solution was concentrated to obtain intermediate 6 (45 mg, crude product). LCMS [M+H]+ m / z: 227.1.

[0097] Step 4: Synthesis of the final product TM-3 Intermediate 3 (68.2 mg, 0.18 mmol, 1.2 equivalents) and intermediate 6 (45.0 mg, approximately 0.15 mmol, 1.0 equivalents) were added sequentially to a 25 mL eggplant-shaped reaction flask equipped with a stirrer. Then, DMF (4 mL) and DIPEA (58.05 mg, 0.45 mmol, 3.0 equivalents) were added. After stirring at room temperature for 10 min, the condensing agent HATU (71.3 mg, 0.187 mmol, 1.25 equivalents) was added, and the mixture was stirred again at room temperature for 1 hour. After the reaction was complete, water was added to quench the reaction mixture. The yellow oily compound TM-3 (58.3 mg, 92.62 μmol, 61.7% yield, 93.5% purity HPLC) was obtained by HPLC purification.

[0098] LCMS [M+H]+ m / z: 588.3.

[0099] 1 H NMR (600 MHz, DMSO- d 6) δ 7.30 – 6.97 (m, 6H), 6.96 – 6.84 (m, 3H), 5.00 (d, J = 7.8 Hz, 1H), 4.43 – 4.18 (m, 3H), 3.80 – 3.74 (m, 6H), 2.81 (ddd, J = 26.9, 12.2, 4.4 Hz, 1H), 2.61 (dd, J = 13.9, 9.5 Hz, 3H), 2.45 (d, J = 16.2 Hz,1H), 2.40 – 2.25 (m, 2H), 2.15 (d, J = 5.8 Hz, 3H), 1.32 (d, J = 6.7 Hz, 2H),1.26 – 1.18 (m, 1H). Example 3: Synthesis of TM-1 Synthesis route:

[0100] Synthesis operation: Step 1: Synthesis of Intermediate 3 A clean, 25 mL oval-shaped flask was used as the reaction vessel. Starting material 1 (800.0 mg, 2.80 mmol) and methylamine hydrochloride solid (189.0 mg, 2.80 mmol) were added sequentially, followed by DMF (8 mL) and DIPEA (1.81 g, 14.02 mmol, 2.44 mL). After stirring at room temperature for 10 min, the condensing agent HATU (1.07 g, 2.80 mmol) was added, and the mixture was stirred again at room temperature for 2 hours. LC-MS monitoring was performed. After the reaction was complete, water (10 mL) was added to quench the reaction. The mixed solution was extracted twice with 15 mL of ethyl acetate, and the resulting organic phases were combined and washed once with brine. The product was then dried with anhydrous sodium sulfate, followed by removal of the organic solvent using a rotary evaporator at 40°C to obtain a yellow oily crude product. HPLC purification yielded a yellow oily intermediate 3 (640.0 mg, 2.14 mmol, 76.50% yield). LCMS [M+H]+ m / z: 299.2 Step 2: Synthesis of Intermediate 4 Intermediate 3 (320.0 mg, 1.07 mmol) was dissolved in dichloromethane (2 mL), and trifluoroacetic acid (2 mL) was added with stirring. The mixture was stirred at room temperature for 30 min, and the reaction was monitored by LC-MS. After the reaction was completed, the solution was concentrated to obtain crude trifluoroacetate intermediate 4 (320.0 mg, crude product) in a pale yellow oil. LCMS [M+H]+ m / z: 199.2.

[0101] Step 3: Synthesis of Intermediate 6 Commercial intermediate 5 (232.0 mg, 1.12 mmol) was added to a 50 mL eggplant-shaped reaction flask equipped with a stirrer, followed by the addition of anhydrous tetrahydrofuran (3 mL) to dissolve it. Then, sodium bicarbonate (282.4 mg, 3.36 mmol) and intermediate 4 (222.2 mg, 1.12 mmol) prepared in the previous step were added sequentially under ice bath conditions. The reaction was stirred at 0 °C for approximately 2 hours, then quenched with water, and extracted twice with ethyl acetate. The organic phases were combined, washed once with saturated brine, and dried over anhydrous sodium sulfate. Concentration and purification yielded a white solid intermediate 6 (168.0 mg, 455.46 μmol, 40.6% yield). LCMS [M+H]+ m / z: 369.2.

[0102] Step 4: Synthesis of Intermediate 7 Intermediate 6 (168.0 mg, 455.46 μmol) was added to a 100 mL eggplant-shaped reaction flask equipped with a stirrer. Then, 2 mL of methanol and 0.5 mL of tap water were added. Next, sodium hydroxide (91.1 mg, 2.28 mmol) was added directly at room temperature. The system was stirred at room temperature for approximately 3 hours. After removing the solvent, the product was obtained, and the pH was adjusted to acidic, precipitating a white solid intermediate 7 (140.0 mg, 86.8% yield). LCMS [M+H]+ m / z: 355.1.

[0103] Step 5: Synthesis of Intermediate 9 A clean, 25 mL oval-shaped flask was used as the reaction vessel. Intermediate 7 (85.6 mg, 241.23 μmol) and commercial reagent 8 (36.0 mg, 241.23 μmol) were added sequentially to the flask, followed by pyridine (2 mL) as a solvent. The mixture was stirred at room temperature for 10 min until the entire system dissolved. Then, the condensing agent EDCI (69.5 mg, 361.85 μmol) was added, and the reaction was carried out for 4 hours. The organic solvent was then removed to obtain a yellow, oily crude product. After purification, a white solid intermediate 9 (35.0 mg, 72.0 μmol, 29.8% yield) was obtained. LCMS [M+H]+ m / z: 486.3.

[0104] Step 6: Synthesis of the final product TM-1 Intermediate 9 (35.0 mg, 72.01 μmol) and 1 mL of anhydrous methanol were added sequentially to a 25 mL eggplant-shaped reaction flask equipped with a stirrer, followed by the addition of 5 mg each of two heterogeneous catalysts: palladium on carbon and palladium hydroxide on carbon. The system was then stirred under a hydrogen atmosphere using a three-way valve with a hydrogen balloon as the hydrogen source for 12 hours. The filtrate was filtered to remove the organic solvent, yielding a pale yellow oily crude product. The crude product was purified by HPLC and lyophilized to obtain the final product TM-1 (6.3 mg, 13.82 μmol, 16.80% yield, 99.1% purity HPLC).

[0105] LCMS [M+H]+ m / z: 452.3.

[0106] 1H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H), 7.57 – 7.44 (m, 2H), 7.36 – 7.20 (m, 2H), 4.54 (s, 1H), 3.16 (dt, J = 13.8, 6.9 Hz, 1H), 2.73 (s,3H), 2.35 (s, 3H), 1.92 (ddt, J = 13.6, 11.1, 5.5 Hz, 1H), 1.81 – 1.62 (m,6H), 1.36 – 1.20 (m, 12H), 0.92 (q, J = 11.7, 10.4 Hz, 2H). Example 4: Synthesis of TM-4 Synthesis route:

[0107] Synthesis operation: Step 1: Synthesis of Intermediate 3 A clean, 100 mL annular flask was used as the reaction vessel. Compound 1 (400.0 mg, 1.82 mmol), DMF (5 mL), and DIPEA (586.9 mg, 4.55 mmol) were added sequentially. The condensing agent HATU (829.9 mg, 2.18 mmol) was added directly under ice bath conditions. The mixture was activated at 0°C for 10 minutes. Then, commercially available compound 2 (387.78 mg, 1.82 mmol) was added directly to the system. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was filtered, and the filtrate was purified and lyophilized to give a white intermediate 3 (388 mg, 934.37 μmol, 51.3% yield). LCMS [M+H]+ m / z: 415.0.

[0108] Step 2: Synthesis of Intermediate 4 A clean, 50 mL oval-shaped flask was used as the reaction vessel. Intermediate 3 (388 mg, 934.37 μmol) was added to the flask. 5 mL of dimethyl sulfoxide (DMSO) was added at room temperature to dissolve the material. Then, methylamine hydrochloride (126.1 mg, 1.869 mmol) and potassium carbonate (322.3 mg, 2.335 mmol) solids were added sequentially, and the stirrer was turned on. The system was then heated in an oil bath at 80 °C for 18 hours. After filtration, the solution was purified and lyophilized to obtain a pale yellow intermediate 4 (200 mg, 469.15 μmol, 50.21% yield). LCMS [M+H]+ m / z: 426.1 Step 3: Synthesis of the final product TM-4 A 25 mL three-necked flask was used as a reactor. Commercial reagent compound 5 (20 mg, 111.13 μmol), potassium fluoride (7.35 mg, 111.13 μmol), and intermediate 4 (47.38 mg, 111.13 μmol) were added to the reactor, followed by the catalyst Pd(dppf)Cl2 (8.1 mg, 11.11 μmol). Then, 4 mL of 1,4-dioxane was added directly. The system was then depressurized with a water pump and purged with nitrogen balloons. This operation was repeated three times to maintain an inert atmosphere. The reaction mixture was heated to 100 °C and reacted for 12 hours. The mixture was quenched with water and extracted twice with ethyl acetate. The combined organic phases were washed twice with brine and then dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated to obtain a pale yellow crude product. The crude product was purified by HPLC to obtain the final product TM-4 (6.5 mg, 13.50 μmol, 12.15% yield, 95.3% purity). LCMS [M+H]+ m / z: 482.2.

[0109] 1 H NMR (600 MHz, Methanol- d 4) δ 8.20 – 8.05 (m, 4H), 7.84 (d, J = 7.8Hz, 1H), 7.28 (dt, J = 10.7, 7.9 Hz, 3H), 7.11 (d, J = 7.8 Hz, 1H), 7.08 – 6.99(m, 2H), 6.93 (d, J = 8.0 Hz, 2H), 6.87 (t, J = 2.0 Hz, 1H), 6.84 (dd, J = 8.1, 2.4Hz, 1H), 3.94 (s, 3H), 3.57 (t, J = 7.2 Hz, 2H), 3.10 (s, 3H), 2.88 (t, J = 7.2Hz, 2H). Example 5: Synthesis of TM-5 Synthesis route:

[0110] Synthesis operation: Step 1: Synthesis of Intermediate 2 A clean, 25 mL orb-shaped flask was used as the reaction vessel. Commercial reagent 1 (600.0 mg, 2.0 mmol) and methylamine hydrochloride (200.0 mg, 2.96 mmol) were added to the reactor. Then, N,N',N'-tetramethylchloromethylammonium hexafluorophosphate (5 mL) was added to fully dissolve the material. Then, N,N',N'-tetramethylchloromethylammonium hexafluorophosphate (1.03 g, 12.55 mmol, 1000 μL) was added. The system was cooled to 0 °C using an ice bath, and N,N',N'-tetramethylchloromethylammonium hexafluorophosphate (675 mg, 2.41 mmol) was added to the system at 0 °C. The reaction mixture was stirred at 0 °C for approximately 1 hour. The reaction was quenched with water. The mixture was extracted three times with ethyl acetate. The combined organic phases were washed once with brine. The mixture was then dried over anhydrous sodium sulfate to remove the organic solvent, yielding a pale yellow, oily crude intermediate 2 (624.0 mg, crude).

[0111] [M+H]+ m / z: 313.1.

[0112] Step 2: Synthesis of Intermediate 3 Intermediate 2 (624 mg, approximately 1.99 mmol) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (5 mL) was added with stirring. The mixture was stirred at room temperature for 30 min, and the reaction was monitored by LC-MS. After the reaction was complete, the solution was evaporated to dryness to obtain a pale yellow, oily crude trifluoroacetate intermediate 3 (800 mg, crude product). LCMS [M+H]+ m / z: 213.1.

[0113] Step 3: Synthesis of Intermediate 5 A clean, 50 mL orb-shaped flask was used as the reaction vessel. Reagent 4 (460.0 mg, 2.01 mmol), crude trifluoroacetate intermediate 3 (800.0 mg, crude), and N-dimethylformamide (5 mL) were added. Then, N-methylimidazole (1.03 g, 12.55 mmol, 1 mL) was added. The system was stirred thoroughly until all materials were dissolved, and then cooled to 0 °C using an ice bath. Reagent N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (671.2 mg, 2.39 mmol) was added to the system at 0 °C, and the reaction mixture was stirred at 0 °C for approximately 1 hour. The reaction was quenched with water. The mixture was extracted three times with ethyl acetate. The combined organic phases were washed once with brine. The mixture was then dried over anhydrous sodium sulfate to remove the organic solvent, yielding a pale yellow, oily crude product. The crude product was purified by HPLC and lyophilized to give intermediate 5 (548.0 mg, 1.29 mmol, 64.88% yield) as a nearly white solid. LCMS [M+H]+ m / z: 423.0.

[0114] Step 4: Synthesis of Intermediate 7 A 50 mL three-necked flask was used as the reactor. A magnetic stirrer was added, and a thermometer was installed at one of the three necks, a reflux tube at the other, and a three-way valve with a nitrogen balloon at the last neck. Commercial reagent compound 6 (100 mg, 366.17 μmol) and intermediate 5 (200.0 mg, 472.05 μmol) were added to the reactor. Then, the catalyst Pd(dppf)Cl2 (36.0 mg, 49.20 μmol) was also added. Next, 8 mL of 1,4-dioxane and 2 mL of tap water were added directly. The system was then depressurized with a water pump and purged with a nitrogen balloon. This operation was repeated three times to maintain an inert atmosphere. The reaction mixture was heated to 80 °C and reacted for 2 hours. The reaction was quenched with water, and the reaction mixture was extracted twice with ethyl acetate. The combined organic phases were washed twice with brine. The mixture was then dried over anhydrous sodium sulfate. The filtrate was filtered to remove the organic solvent, yielding a pale yellow crude product. The crude product was purified to give intermediate 7 (142.0 mg, 67.9% yield). LCMS [M+H]+ m / z: 572.2.

[0115] Step 5: Synthesis of the final product TM-5

[0116] Intermediate 7 (142.0 mg, 248.23 μmol) and commercial reagent 8 (33.5 mg, 248.23 μmol) were added sequentially to a 25 mL eggplant-shaped reaction flask equipped with a stirrer. Then, 5 mL of anhydrous methanol and glacial acetic acid (21.0 mg, 349.37 μmol, 20 μL) were added to fully dissolve the materials. The reaction mixture was then stirred at room temperature for 3 hours. Sodium borohydride (20.0 mg, 528.65 μmol) was then added at room temperature, and the reaction was continued with stirring at room temperature for approximately 1 hour. After removing the organic solvent, a pale yellow crude product was obtained. The crude product was purified by HPLC and lyophilized to give the final product TM-5 as a brown solid (103.0 mg, 148.85 μmol, 59.97% yield, 99.9% purity HPLC). LCMS [M+H]+ m / z: 691.2.

[0117] 1 H NMR (400 MHz, DMSO- d 6) δ 8.16 (s, 1H), 7.87 (t, J = 1.7 Hz, 1H), 7.81(t, J = 1.6 Hz, 1H), 7.71 (t,J = 1.6 Hz, 1H), 7.39 (dd, J = 8.3, 2.9 Hz, 6H), 7.32(q, J = 3.6 Hz, 3H), 7.06 (t, J = 7.9 Hz, 1H), 6.71 – 6.60 (m, 2H), 6.59 – 6.44(m, 1H), 5.50 (s, 2H), 5.40 (t, J = 7.3 Hz, 1H), 4.41 (s, 2H), 3.23 (s, 6H), 2.81 – 2.61 (m, 3H), 2.53 (s, 3H), 1.09 (d, J = 6.9 Hz, 6H). Experiment 6: Surface Plasmon Resonance Experiment Freshly prepared recombinant hAPOL2-Strep protein was immobilized on the surface of Sensor Chip CM5 (cytiva) using an amino-coupling kit (cytiva) with a Biacore T200 instrument (cytiva). Compounds TM-1 to TM-5 prepared in Examples 1 to 5 were prepared with buffer (PBSP + 5% DMSO) at concentrations of 0.1, 0.2, 0.39, 0.78, 1.56, 3.125, 6.25, 12.5, 25, 50, and 100 μM, and then contacted with the above-mentioned recombinant hAPOL2-Strep protein.

[0118] The binding affinity of hAPOL2-Strep protein to analyte compounds TM-1 to TM-5 was detected using a Biacore T200 instrument, and the dissociation constant K was calculated using Biacore T200 Evaluation software (Cytiva). D Dissociation constant K D The calculations were performed using Biacore T200 Evaluation Software (Version 3.1).

[0119] The experimental calculation results are shown in Table 1. Table 1

[0120] As shown in Table 1, the dissociation constants K of compounds TM-1 to TM-5 of the present invention with recombinant hAPOL2-Strep protein are... D All less than 9.93×10 -5This indicates that compounds TM-1 to TM-5 of the present invention have a strong affinity for recombinant hAPOL2-Strep protein; among them, compounds TM-1, TM-2, TM-3, and TM-5 exhibit a relatively stronger binding ability to recombinant hAPOL2-Strep protein.

[0121] Test Example 9: Cytotoxicity Detection Assay 5x10 3 A549 human non-small cell lung cancer cells were seeded in 96-well plates and incubated in a CO2 incubator for 24 hours for later use; stock solutions of compounds TM-1 to TM-5 of this application were prepared with DMSO for later use. Test group: The prepared solutions of compounds TM-1 to TM-5 of this application were added to the 96-well plates inoculated with A549 human non-small cell lung cancer cells to working concentrations of 11 μM, 33 μM, and 100 μM, respectively. Control group (DMSO): An equal volume of DMSO was added to the 96-well plates inoculated with A549 human non-small cell lung cancer cells. Blank group: Cell-free medium containing an equal volume of DMSO was used as the blank group. Each experiment was repeated three times; cell viability in the test and control groups was detected using a CCK-8 assay kit to evaluate the toxicity of TM-1 to TM-5 of this application to A549 human non-small cell lung cancer cells. Survival rate calculation formula: Cell Viability % = (OD Test -OD Blank ) / (OD DMSO -OD Blank )×100%; The test results are as follows Figures 1-5 As shown, Figures 1-5 The images are bar charts showing the viability of compounds TM-1 to TM-5 of this application against non-small cell lung cancer cells from 549 individuals. from Figures 1-5 It can be seen that the experimental groups containing compounds TM-1~TM-5 of this application showed significantly lower cell viability of A549 human non-small cell lung cancer cells compared to the DMSO control group, exhibiting strong and significant cytotoxicity. With increasing concentrations of compounds TM-1~TM-5 of this application, the cell viability of A549 human non-small cell lung cancer cells decreased significantly.

[0122] Other compounds in this application have similar beneficial effects as described above.

[0123] Other cancer cell toxicity tests of the compound of Formula I showed that it had similar effects to those described above.

Claims

1. The compound represented by Formula I, or its stereoisomer, its deuterated compound, or its pharmaceutically acceptable salt: A-(L1) n - B - (L2) m - C (Formula I); In formula I, n and m are each independent integers selected from 0, 1, 2, 3, 4, 5, 6, 7, and 8; A, B, and C are each independently selected from 5-10 membered aromatic rings, 5-10 membered aromatic heterocycles, 3-10 membered cycloalkyl groups, and 3-10 membered alkyl heterocycles; L1 and L2 are each independently selected from - R 3 -C(O)-R 4 -、- R 3 -C(O)NR 5 R 4 -、- R 3 -C(O)OR 4 -、- R 3 - OR 4 -、- R 3 -NR 4 R 5 -、-(CH2) 0~4 -、-C 3~10 cycloalkyl, -C 3~10 Heterocyclic alkyl; the R 3 R 4 R 5 Selected independently from hydrogen and -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 The alkynyl group may not exist. Preferably, A, B, and C can be further optionally defined by one or more independent R... 1 replace; L1 and L2 can be further optionally defined by one or more independent R... 2 replace; in, The R 1 R 2 Each group is independently selected from hydrogen, halogen, cyano, nitro, and -C. 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group, -C 0~4 Alkylene-OR 12 -C 0~4 Alkylene-OC(O)R 12 -C 0~4 Alkylene-SR 12 -C 0~4 Alkylene-S(O)2R 12 -C 0~4 Alkylene-S(O)R 12 -C 0~4 Alkylene-S(O)2NR 12 R 13 -C 0~4 Alkylene-S(O)NR 12 R 13 -C 0~4 Alkylene-C(O)R 12 -C 0~4 Alkylene-C(O)OR 12 -C 0~4 Alkylene-C(O)NR 12 R 13 -C 0~4 Alkylene-NR 12 R 13 -C 0~4 Alkylene-NR 12 C(O)R 13 -C 0~4 Alkylene-NR 12 S(O)2R 13 -C 0~4 Alkylene-NR 12 S(O)R 13 -C 0~4 Alkylene (3- to 10-membered cycloalkyl), -C 0~4 Alkylene (3- to 10-membered heterocyclic alkyl), -C 0~4 alkylene-(6-10 membered aromatic ring), -C 0~4 Alkylene rings (5-10 membered heteroaryl rings); R 12 R 13 Selected independently from hydrogen and -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group, -C 0~4 Alkylene (3- to 10-membered cycloalkyl), -C 0~4 Alkylene (3- to 10-membered heterocyclic alkyl), -C 0~4 alkylene-(6-10 membered aromatic ring), -C 0~4 Alkylene (5-10 membered heteroaryl ring); wherein the alkylene, cycloalkyl, heterocycloalkyl, aromatic ring, or heteroaryl ring may be optionally surrounded by one, two, three, or four independent R... 14 replace; The R 14 Each group is independently selected from hydrogen, halogen, cyano, nitro, and -C. 1~6 alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group, -C 0~4 Alkylene (3- to 10-membered cycloalkyl), -C 0~4 Alkylene (3- to 10-membered heterocyclic alkyl), -C 0~4 alkylene-(6-10 membered aromatic ring), -C 0~4 Alkylene rings (5-10 membered heteroaryl rings). More preferably, A, B, and C are each independently selected from 6-membered aromatic rings, 6-membered aromatic heterocycles, 6-membered cycloalkyl groups, and 6-membered alkyl heterocycles. More preferably, L1 and L2 are each independently selected from: 。 More preferably, the R 1 R 2 Each is independently selected from hydrogen, chlorine, fluorine, methyl, ethyl, isopropyl, methoxy, ethoxy, benzoxy, m-isopropylaniline, methyl, and dimethylamino.

2. The compound according to claim 1, characterized in that: A is a benzene ring or a pyrimidine ring, B is a benzene ring or a piperidine ring, and C is a benzene ring. Alternatively, n can be 0 or 1; L1 is selected from: 。 Alternatively, m can be 1, 2, 3, or 4; L2 is selected from: 。 3. The compound according to claim 1, characterized in that, A, B, and C are benzene rings; The n is 1; the L1 is selected from: ; The m is 3 or 4; the L2 is selected from: 。 Preferably, The R 1 Selected from hydrogen, chlorine, methyl, and methoxy; The R 2 Selected from hydrogen, fluorine, and methyl.

4. The compound according to claim 1, characterized in that: A, B, and C are benzene rings; The n is 1; the L1 is selected from: ; The value of m is 4; the L2 is selected from: ; The R 1 Selected from hydrogen and methyl; The R 2 Selected from hydrogen, fluorine, and methyl.

5. The compound according to claim 1, or its stereoisomer, its deuterated compound, or its pharmaceutically acceptable salt, wherein, The compound shown in Formula I has any one of the following structures: (I-1) to (I-5) A -L1- B -L2 - C (Equation I-1) Wherein, A is cyclohexyl, and B is... C is a phenyl group; L1 is selected from -R 3 -N(R 4 )R 5 -, L2 is selected from - R 3 -C(O)N(R 5 )R 4 -; The R 3 R 4 R 5 Selected independently from hydrogen and -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 The alkynyl group may not be present; The C may be further optionally defined by one or more independent Rs. 1 Replace, R 1 Independently selected from hydrogen, halogen, cyano, nitro, -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group; The L1 can be further optionally defined by one or more independent Rs. 2 Replace; the R 2 Independent selection from -C 0~4 Alkylene-C(O)OR 12 -C 0~4 Alkylene-C(O)NR 12 R 13 -C 0~4 Alkylene-NR 12 R 13 The R 12 R 13 Selected independently from hydrogen and -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group; A -L1- B-(L2)4-C (Formula I-2) Wherein, A, B, and C are all phenyl groups, and the phenyl groups may be optionally converted by one or more independent R groups. 1 Replace, R 1 Independently selected from hydrogen, halogen, cyano, nitro, -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group; L1 is -R 3 -OR 4 -,-(L2)4 -for-R 3 -C(O)N(R 5 )R 4 -C 3~10 cycloalkyl-R 3 -C(O)N(R 5 )R 4 -R 3 -OR 4 -, where C 3~10 The cycloalkyl group may be further optionally replaced by one or more independent R 2 Instead, the R 2 Independently selected from hydrogen, halogen, cyano, nitro, -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group, -C 0~4 Alkylene-OR 12 , The R 3 R 4 R 5 Selected independently from hydrogen and -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 The alkynyl group may not be present; A -L1- B-(L2)2-C (Formula I-3) Wherein, A, B, and C are all phenyl groups, and the phenyl groups may be optionally converted by one or more independent R groups. 1 Replace, R 1 Independently selected from hydrogen, halogen, cyano, nitro, -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group, -C 0~4 Alkylene-OR 12 ; L1 is selected from -R 3 -N(R 4 )R 5 -,-(L2)2 - selected from -R 3 -OR 4 -R 3 -C(O)N(R 5 )R 4 -; The R 3 R 4 R 5 Selected independently from hydrogen and -C 1~6 Alkyl groups may not be present; The L2 can be further optionally defined by one or more independent Rs. 2 Replace; the R 2 Independent selection from -C 0~4 Alkylene-C(O)OR 12 -C 0~4 Alkylene-C(O)NR 12 R 13 ; The R 12 R 13 Selected independently from hydrogen and -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group; A -L1- B - C (Equation I-4) Wherein, A and C are both phenyl, and B is... ; A, B, and C can be further arbitrarily selected by one or more independent R... 1 Replace, R 1 Independently selected from hydrogen, halogen, cyano, nitro, -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group, -C 0~4 Alkylene-OR 12 -C 0~4 Alkylene-C(O)OR 12 -C 0~4 Alkylene-C(O)NR 12 R 13 -C 0~4 Alkylene-NR 12 R 13 ; R 12 R 13 Selected independently from hydrogen and -C 1~6 Alkyl, -C 0~4 Alkylene (6-10 membered aromatic rings); L1 is selected from -R 4 -N(R 5 )C(O)R 3 -, the R 3 R 4 R 5 Selected independently from hydrogen and -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 The alkynyl group may not be present; A - B - L2 - C (Equation I-5) The A is B is C is a phenyl group; A, B, and C can be further arbitrarily selected by one or more independent R... 1 Replace, R 1 Independently selected from hydrogen, halogen, cyano, nitro, -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group, -C 0~4 Alkylene-OR 12 -C 0~4 Alkylene-C(O)OR 12 -C 0~4 Alkylene-C(O)NR 12 R 13 -C 0~4 Alkylene-NR 12 R 13 ; L2 is -R 3 -C(O)N(R 5 )R 4 -, the R 3 R 4 R 5 Selected independently from hydrogen and -C 1~6 Alkyl, -C 2~6 alkenyl, -C 2~6 The acetylin group may not be present. The L2 can be further optionally defined by one or more independent Rs. 2 Replace; the R 2 Independent selection from -C 0~4 Alkylene-C(O)OR 12 -C 0~4 Alkylene-C(O)NR 12 R 13 -C 0~4 Alkylene-NR 12 R 13 ; The R 12 R 13 Selected independently from hydrogen and -C 1~6 Alkyl, -C 0~4 Alkylene (6-10 membered aromatic ring); wherein the aromatic ring may be optionally surrounded by one, two, three or four independent R... 14 replace; The R 14 Each group is independently selected from hydrogen, halogen, cyano, nitro, and -C. 1~6 Alkyl groups.

6. The compound according to any one of claims 1 to 5, characterized in that: The compound is: TM-2, TM-3 TM-1, TM-4 TM-5.

7. A method for preparing the compound according to claim 5 or 6, or its stereoisomer, its deuterated compound, or its pharmaceutically acceptable salt, wherein the preparation method comprises: Methods for preparing the compound represented by formula (I-1), its stereoisomer, its deuterated compound, or its pharmaceutically acceptable salt: Compound I-1-1 was deprotected to yield compound I-1-2. Compound I-1-2 and compound I-1-3 were coupled to yield compound I-1-4. Further hydrolysis yielded compound I-1-5. Compound I-1-5 and compound I-1-6 were acylated to prepare compound (I-1), where T is an amino protecting group, X is a halogen, and M is a carbon group. 1~6 alkyl: Methods for preparing the compound shown in formula (I-2), its stereoisomer, its deuterated compound, or its pharmaceutically acceptable salt: Compound I-2-1 is protected by a protecting group to obtain compound I-2-2. Further alkylation yields compound I-2-3. Compound I-2-4 undergoes silylation in the presence of a Lewis acid catalyst and trimethylcyanosilane to obtain compound I-2-5. Further hydrolysis yields compound I-2-6. Compound I-2-6 is reacted with a reducing agent to generate compound I-2-7. Further addition of a carboxyl protecting group yields compound I-2-8. Removal of the amino protecting group yields compound I-2-9. Compound I-2-9 reacts with compound I-2-10 via acylation to obtain compound I-2-11. Further nucleophilic substitution yields compound I-2-12. Removal of the carboxyl protecting group yields compound I-2-13. Compound I-2-13 reacts with compound I-2-3 via acylation to obtain compound (I-2), where T is an amino protecting group, W is a hydroxyl protecting group, Z is a carboxyl protecting group, and M is a C6 protecting group. 1~6 Alkyl group, Q is C 3~10 Cycloalkyl: Methods for preparing the compound represented by formula (I-3), its stereoisomer, its deuterated compound, or its pharmaceutically acceptable salt: Compound I-3-3 is obtained by condensation and reduction of compound I-3-1 and compound I-3-2. Compound I-3-3 and compound I-3-4 are then acylated to obtain compound (I-3). Methods for preparing the compound shown in formula (I-4), its stereoisomer, its deuterated compound, or its pharmaceutically acceptable salt: Compound I-4-3 is obtained by acylation of compound I-4-1 and compound I-4-2. Compound I-4-3 then reacts with a boric acid compound containing a cyclic C structure to obtain compound (I-4), where X is a halogen, such as fluorine, chlorine, or bromine. Methods for preparing the compound shown in formula (I-5), its stereoisomer, its deuterated compound, or its pharmaceutically acceptable salt: Compound I-5-3 is obtained by acylation of compound I-5-1 and compound I-5-2. Compound I-4-3 reacts with a boric acid compound containing a ring A structure to obtain compound (I-5), where X is a halogen, such as fluorine, chlorine, or bromine. 。 8. A pharmaceutical composition comprising a therapeutically effective amount of at least one of the compounds of any one of claims 1-7, or a stereoisomer thereof, or a deuterated compound thereof, or a pharmaceutically acceptable salt thereof.

9. Use of the compound according to any one of claims 1 to 7, or its stereoisomer, or its deuterated compound, or its pharmaceutically acceptable salt, or the pharmaceutical composition according to claim 8, in the preparation of a medicament for treating diseases related to abnormal cell proliferation. Preferably, the diseases related to abnormal cell proliferation are selected from tumors. Preferably, the tumor is a solid tumor or a non-solid tumor. Preferably, the drug is a drug that targets APOL2.

10. Use of the compound of Formula I according to any one of claims 1 to 7, or a stereoisomer thereof, or a deuterated compound thereof, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 8, in the preparation of a medicament for treating cancer in an individual or delaying the progression of cancer in an individual. Preferably, the drug is a drug that targets APOL2.